XML 62 R55.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Financial Data for Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Research and development expenses $ 13,648     $ 18,864     $ 45,244 $ 45,362
General and administrative expenses 6,039     6,276     18,754 18,883
Net loss (18,234) $ (21,006) $ (19,680) (22,441) $ (18,798) $ (16,486) (58,920) (57,725)
Reportable Segment                
Segment Reporting Information [Line Items]                
General and administrative expenses 6,039     6,276     18,754 18,883
Other segment items [1] (1,453)     (2,699)     (5,078) (6,520)
Net loss (18,234)     (22,441)     (58,920) (57,725)
ACR-368 | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development expenses 3,985     11,098     17,645 24,097
ACR-2316 | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development expenses [2] 2,628     1,735     5,558 1,735
Other Drug Discovery Programs | Reportable Segment                
Segment Reporting Information [Line Items]                
Research and development expenses 496     368     1,705 3,490
Personnel | Reportable Segment                
Segment Reporting Information [Line Items]                
Indirect research and development expenses 5,215     4,510     16,367 13,031
Facilities Supplies And Other | Reportable Segment                
Segment Reporting Information [Line Items]                
Indirect research and development expenses $ 1,324     $ 1,153     $ 3,969 $ 3,009
[1] Other segment items consist of interest income and other (expense) income, net. Interest income consists of interest income earned on cash equivalents and investments and amortization of premiums and accretion of discounts to maturity for available-for-sale debt securities. Other (expense) income, net primarily consists of realized and unrealized gains and losses on foreign currency transactions, state taxes, and investment management fees.
[2] ACR-2316 direct research and development expenses include costs related to the Company’s novel, internally-discovered second clinical stage asset, which was promoted to a development program upon being granted IND clearance in the third quarter of 2024 and includes clinical trial and related activities. Prior to IND clearance, costs related to preclinical drug discovery activities progression related to ACR-2316 were included in other drug discovery programs direct research and development expenses.